| # | Title | Journal | Year | Citations |
|---|
| 1 | A review of central 5-HT receptors and their function | Neuropharmacology | 1999 | 2,851 |
| 2 | The metabotropic glutamate receptors: Structure and functions | Neuropharmacology | 1995 | 2,138 |
| 3 | Goal-directed instrumental action: contingency and incentive learning and their cortical substrates | Neuropharmacology | 1998 | 1,313 |
| 4 | Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine | Neuropharmacology | 1986 | 1,247 |
| 5 | CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury | Neuropharmacology | 2000 | 1,217 |
| 6 | Transport of brain-derived neurotrophic factor across the blood–brain barrier | Neuropharmacology | 1998 | 1,150 |
| 7 | Pharmacological agents acting at subtypes of metabotropic glutamate receptors | Neuropharmacology | 1999 | 1,025 |
| 8 | Structural plasticity associated with exposure to drugs of abuse | Neuropharmacology | 2004 | 1,014 |
| 9 | GABAA receptors: Subtypes provide diversity of function and pharmacology | Neuropharmacology | 2009 | 836 |
| 10 | Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data | Neuropharmacology | 1999 | 832 |
| 11 | Towards a glutamate hypothesis of depression | Neuropharmacology | 2012 | 831 |
| 12 | Imaging dopamine's role in drug abuse and addiction | Neuropharmacology | 2009 | 825 |
| 13 | Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following c fibre stimulation. | Neuropharmacology | 1987 | 787 |
| 14 | Dopamine and drug addiction: the nucleus accumbens shell connection | Neuropharmacology | 2004 | 777 |
| 15 | 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist | Neuropharmacology | 1999 | 712 |
| 16 | Mechanisms of ischemic brain damage | Neuropharmacology | 2008 | 708 |
| 17 | BDNF – a key transducer of antidepressant effects | Neuropharmacology | 2016 | 701 |
| 18 | Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier | Neuropharmacology | 2001 | 700 |
| 19 | Neuroprotection for ischemic stroke: Past, present and future | Neuropharmacology | 2008 | 672 |
| 20 | Distinctive pharmacology and kinetics of cloned neuronal Ca2+ channels and their possible counterparts in mammalian CNS neurons | Neuropharmacology | 1993 | 638 |
| 21 | Structure and function of the NMDA receptor channel | Neuropharmacology | 1995 | 616 |
| 22 | Molecular biology of 5-HT receptors | Neuropharmacology | 1994 | 608 |
| 23 | Reward and aversion in a heterogeneous midbrain dopamine system | Neuropharmacology | 2014 | 606 |
| 24 | Therapeutics of Alzheimer's disease: Past, present and future | Neuropharmacology | 2014 | 601 |
| 25 | Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse | Neuropharmacology | 2007 | 593 |
| 26 | Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity | Neuropharmacology | 2008 | 570 |
| 27 | Metabotropic glutamate receptors: From the workbench to the bedside | Neuropharmacology | 2011 | 559 |
| 28 | Serotonin and appetite | Neuropharmacology | 1984 | 557 |
| 29 | The Yin and Yang of dopamine release: a new perspective | Neuropharmacology | 2007 | 546 |
| 30 | Stimulation of food intake by muscimol and beta endorphin | Neuropharmacology | 1977 | 541 |
| 31 | Molecular mechanisms of drug addiction | Neuropharmacology | 2004 | 538 |
| 32 | Cannabinoid physiology and pharmacology: 30 years of progress | Neuropharmacology | 2004 | 531 |
| 33 | A nomenclature for ligand-gated ion channels | Neuropharmacology | 2009 | 531 |
| 34 | The past, present and future of purine nucleotides as signalling molecules | Neuropharmacology | 1997 | 530 |
| 35 | Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid | Neuropharmacology | 2007 | 525 |
| 36 | The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies | Neuropharmacology | 2004 | 523 |
| 37 | Neuropeptides — an overview | Neuropharmacology | 2000 | 519 |
| 38 | Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist | Neuropharmacology | 2005 | 500 |
| 39 | Executive function and PTSD: Disengaging from trauma | Neuropharmacology | 2012 | 495 |
| 40 | Models of the diffusional spread of nitric oxide: Implications for neural nitric oxide signalling and its pharmacological properties | Neuropharmacology | 1994 | 492 |
| 41 | BDNF-induced local protein synthesis and synaptic plasticity | Neuropharmacology | 2014 | 492 |
| 42 | Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP | Neuropharmacology | 2005 | 487 |
| 43 | Biological substrates of reward and aversion: A nucleus accumbens activity hypothesis | Neuropharmacology | 2009 | 483 |
| 44 | SB 242084, a Selective and Brain Penetrant 5-HT 2C Receptor Antagonist | Neuropharmacology | 1997 | 480 |
| 45 | Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability | Neuropharmacology | 2015 | 473 |
| 46 | Dopamine receptors and brain function | Neuropharmacology | 1996 | 469 |
| 47 | Individual differences in the attribution of incentive salience to reward-related cues: Implications for addiction | Neuropharmacology | 2009 | 469 |
| 48 | Tissue distribution of the P2X7 receptor | Neuropharmacology | 1997 | 467 |
| 49 | Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex | Neuropharmacology | 2002 | 465 |
| 50 | Signaling pathways underlying the rapid antidepressant actions of ketamine | Neuropharmacology | 2012 | 460 |
